Rallis India reported its Q4 and full-year FY26 financial results during an Analyst/Investors Earnings Conference Call held on April 28, 2026. The call was addressed by Dr. Gyanendra Shukla, Managing Director and CEO, and Mr. Bhaskar Swaminathan, Chief Financial Officer. The company delivered a reasonable performance despite a short Rabi season, geopolitical unrest, and ongoing global supply chain disruptions.

Q4FY26 Financial Performance

For the quarter ended March 31, 2026, Rallis India posted revenue of ₹456 cr, compared to ₹430 cr in Q4FY25, representing overall growth of approximately 6%. Volume growth stood at approximately 5% with pricing contributing approximately 1%. The following table summarises key financial metrics for Q4FY26:

Exceptional items for the quarter included a profit on sale of property of Aurangabad Land of ₹3 cr.

Segment-Wise Q4FY26 Performance

The Crop Care segment grew 5% to ₹425 cr in Q4FY26 from ₹405 cr in Q4FY25, driven by volume expansion, new product promotion, and increased digital engagement. Within the domestic B2C business, revenue grew 15% to ₹255 cr from ₹222 cr in Q4FY25, primarily led by volume growth of 14% in insecticides. The Soil & Plant Health (SPH) category registered robust growth of 27% to ₹47 cr from ₹37 cr, with volume growth of 29% driven by Micronutrients and Biofertilizers.

The Seeds business delivered revenue growth of 23% to ₹31 cr from ₹25 cr in Q4FY25, supported by 8% volume growth and 15% price growth, mainly driven by cotton and millets. On the B2B side, exports de-grew 33% to ₹77 cr from ₹114 cr due to volume and revenue decline in Metribuzin and Pendimethalin. However, the CSM (Contract and Specialty Manufacturing) business recorded strong growth of 59% to ₹66 cr from ₹41 cr, driven by both volume and price growth. Total B2B revenue stood at ₹170 cr versus ₹182 cr, a decline of 7% primarily due to volumes.

Full-Year FY26 Performance

For the full financial year FY26, Rallis India's topline revenue stood at ₹2897 cr, reflecting 9% year-on-year growth. Crop Care revenue stood at ₹2416 crore, reflecting 8% growth year-on-year, driven by volume expansion despite price softness. Seeds revenue increased to ₹481 crore, delivering 15% growth year-on-year, supported by cotton and maize along with improved contribution from in-licensed products.

The B2C business recorded growth of 5%, delivering ₹1657 cr of revenue, primarily contributed by 9% volume growth. The B2B business recorded growth of 14%, delivering ₹759 cr of revenue, supported by both volume and price growth and expansion of the customer base. On a yearly basis, the herbicide business grew by 15%, fungicide by 5%, while insecticide declined by 3%.

The company maintained a healthy cash and liquid balance of ₹541 cr as of March 31, 2026. Inventory levels remained slightly elevated compared to the same quarter of the previous year, while collection cycles remained smooth.

New Products, Initiatives and Operational Highlights

During the quarter, Rallis India launched several new products and digital initiatives:

• ALSTOR: A dual action granular insecticide
• FIPLAM: A broad-spectrum formulation designed to manage both sucking and chewing pests
• Spiro: A three-way patented herbicide for Paddy (registration obtained)
• Seeds: Two new products launched across core crops
• Idea2Impact platform: An open innovation ecosystem to source, validate, and commercialise agri-innovations
• Saksham (GIS platform): Enables scientific identification of high-potential villages for targeted market expansion
• Sampark Plus: Captures farmer-level demand signals to generate actionable insights and improve sales conversion

The company also reported record production levels as a result of improved manufacturing efficiency and operational excellence. Overall annual capacity utilisation improved in FY26 compared to FY25.

Industry Landscape and Key Risk Factors

Management highlighted that the Indian agrochemical sector is transitioning from a buyers' to a sellers' market due to war-induced supply constraints and rising prices. Key agrochemicals, particularly Glyphosate (up approximately 25%), are facing rising costs from inflation-driven pass-throughs and China supply disruptions. Raw material cost increases of 15% to 25% have been observed across the portfolio.

On the agricultural outlook, the IMD's 2026 monsoon forecast at 92% of Longest Period Average (LPA) signals below-normal rains, with rising El Niño odds driving early deficits in North, Central, and Western India. As of end of March 2026, summer sowing was progressing at a slower pace, down 4.7% year-on-year, primarily driven by declines in Rice (-7.1%), Cereals (-3.8%), and Oilseeds (-6.1%). Unseasonal rains and hailstorms damaged Rabi crops across 2.49 lakh hectares, with wheat suffering the maximum impact. The global crop protection market is estimated at approximately USD 70–75 billion in 2026 and is projected to grow at a CAGR of around 5.0–5.5%.

Management noted that the company is focused on securing Kharif supply, passing on cost increases where possible, maintaining calibrated inventory build-up, and driving portfolio rationalisation across both Crop Care and Seeds segments. The Seeds business is focusing on five strategic crops: Cotton, Maize, Millet, Mustard, and Rice.

Rallis India Limited has formally announced its schedule of meetings with analysts and institutional investors for May-June 2026, as required under Regulation 30(6) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company communicated this information to both BSE Limited and National Stock Exchange of India Limited on April 30, 2026.

Meeting Schedule and Participants

The company has outlined a comprehensive engagement plan with key market participants over the two-month period. The schedule includes both individual meetings and participation in major industry conferences.

Regulatory Compliance and Information Sharing

Rallis India has emphasized its commitment to regulatory compliance by providing advance notice of these meetings as mandated by SEBI regulations. The company has specifically stated that no unpublished price sensitive information will be shared during any of the scheduled analyst or investor meetings.

Schedule Flexibility

The company has noted that the meeting schedule is subject to change due to potential exigencies on the part of analysts, institutional investors, or the company itself. This flexibility clause ensures that all parties can accommodate any unforeseen circumstances that may arise.

Corporate Communication

The formal communication was signed by Sariga P Gokul, Company Secretary & Compliance Officer, and digitally authenticated on April 30, 2026. All meetings are planned to be conducted in Mumbai, providing convenient access for the financial community based in India's commercial capital.